These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 35431132)

  • 1. The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial.
    Daneshmand S; Brummelhuis ISG; Pohar KS; Steinberg GD; Aron M; Cutie CJ; Keegan KA; Maffeo JC; Reynolds DL; Raybold B; Chau A; Witjes JA
    Urol Oncol; 2022 Jul; 40(7):344.e1-344.e9. PubMed ID: 35431132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant Chemotherapy.
    Grivas P; Koshkin VS; Chu X; Cole S; Jain RK; Dreicer R; Cetnar JP; Sundi D; Gartrell BA; Galsky MD; Woo B; Li-Ning-Tapia E; Hahn NM; Carducci MA
    Eur Urol Oncol; 2024 Aug; 7(4):914-922. PubMed ID: 38155060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer.
    Narayan V; Mamtani R; Keefe S; Guzzo T; Malkowicz SB; Vaughn DJ
    Cancer Res Treat; 2016 Jul; 48(3):1084-91. PubMed ID: 26639198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.
    Funt SA; Lattanzi M; Whiting K; Al-Ahmadie H; Quinlan C; Teo MY; Lee CH; Aggen D; Zimmerman D; McHugh D; Apollo A; Durdin TD; Truong H; Kamradt J; Khalil M; Lash B; Ostrovnaya I; McCoy AS; Hettich G; Regazzi A; Jihad M; Ratna N; Boswell A; Francese K; Yang Y; Folefac E; Herr HW; Donat SM; Pietzak E; Cha EK; Donahue TF; Goh AC; Huang WC; Bajorin DF; Iyer G; Bochner BH; Balar AV; Mortazavi A; Rosenberg JE
    J Clin Oncol; 2022 Apr; 40(12):1312-1322. PubMed ID: 35089812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Safety, Tolerability, and Preliminary Efficacy of a Gemcitabine-releasing Intravesical System (TAR-200) in American Urological Association-defined Intermediate-risk Non-muscle-invasive Bladder Cancer Patients: A Phase 1b Study.
    P van Valenberg FJ; van der Heijden AG; Cutie CJ; Bhanvadia S; Keegan KA; Hampras S; Sweiti H; Maffeo JC; Jin S; Chau A; Reynolds DL; Iarossi C; Kelley A; Li X; Stromberg KA; Michiel Sedelaar JP; Steenbruggen JJO; Somford DM; Alfred Witjes J
    Eur Urol Open Sci; 2024 Apr; 62():8-15. PubMed ID: 38585206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant Cisplatin-Based Chemotherapy Followed by Selective Bladder Preservation Chemoradiotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder: Post Hoc Analysis of Two Prospective Studies.
    Cho SW; Lim SH; Kwon GY; Kim CK; Park W; Pyo H; Chung JH; Song W; Sung HH; Jeong BC; Park SH
    Cancer Res Treat; 2024 Jul; 56(3):893-897. PubMed ID: 38374699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bladder-sparing treatment using tislelizumab combined with gemcitabine/cisplatin in selected patients with muscle-invasive bladder cancer: a real-world study.
    Luo C; Luo S; Wusimanjiang W; Wang Z; Liu P; Wang B; Yuan D; Lin H; Xu A; Deng N; Wu K; Zhu X; Xu P; Chen J; Huang B
    Clin Transl Oncol; 2024 Jul; 26(7):1759-1767. PubMed ID: 38472556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of Response Following Neoadjuvant Cisplatin-Based Chemotherapy for Muscle Invasive Urothelial Bladder Cancer Using Molecular Profile: A Prospective Clinical Study.
    Elkarta A; Awadalla A; El-Hefnawy A; Mosbah A; Abolenein H; Shokeir A
    Clin Genitourin Cancer; 2024 Apr; 22(2):38-46.e1. PubMed ID: 37758560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695).
    Flaig TW; Tangen CM; Daneshmand S; Alva AS; Lucia MS; McConkey DJ; Theodorescu D; Goldkorn A; Milowsky MI; Bangs R; MacVicar GR; Bastos BR; Fowles JS; Gustafson DL; Plets M; Thompson IM; Lerner SP
    Eur Urol; 2023 Sep; 84(3):341-347. PubMed ID: 37414705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an
    Satkunasivam R; Lim K; Teh BS; Guzman J; Zhang J; Farach A; Chen SH; Wallis CJ; Efstathiou E; Esnaola NF; Sonpavde GP
    Future Oncol; 2022 Aug; 18(25):2771-2781. PubMed ID: 35703113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant Chemoradiotherapy Followed by Radical Cystectomy for Muscle-Invasive Bladder Cancer: Analysis of Efficacy and Safety in 119 Patients.
    Fujiwara M; Tanaka H; Kobayashi M; Nakamura Y; Fan B; Ishikawa Y; Fukuda S; Toda K; Yoshida S; Yokoyama M; Yoshimura R; Fujii Y
    Clin Genitourin Cancer; 2024 Apr; 22(2):193-200.e1. PubMed ID: 38000954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for failing to complete gemcitabine-cisplatin neoadjuvant chemotherapy in muscle invasive bladder cancer patients.
    Kang H; Suh J; You D; Jeong IG; Hong B; Hong JH; Ahn H; Lim B
    Investig Clin Urol; 2024 May; 65(3):256-262. PubMed ID: 38714516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer.
    Beckabir W; Zhou M; Lee JS; Vensko SP; Woodcock MG; Wang HH; Wobker SE; Atassi G; Wilkinson AD; Fowler K; Flick LM; Damrauer JS; Harrison MR; McKinnon KP; Rose TL; Milowsky MI; Serody JS; Kim WY; Vincent BG
    Nat Commun; 2024 May; 15(1):4448. PubMed ID: 38789460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer.
    Yuh BE; Ruel N; Wilson TG; Vogelzang N; Pal SK
    J Urol; 2013 May; 189(5):1682-6. PubMed ID: 23123547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.
    Galsky MD; Daneshmand S; Izadmehr S; Gonzalez-Kozlova E; Chan KG; Lewis S; Achkar BE; Dorff TB; Cetnar JP; Neil BO; D'Souza A; Mamtani R; Kyriakopoulos C; Jun T; Gogerly-Moragoda M; Brody R; Xie H; Nie K; Kelly G; Horowitz A; Kinoshita Y; Ellis E; Nose Y; Ioannou G; Cabal R; Del Valle DM; Haines GK; Wang L; Mouw KW; Samstein RM; Mehrazin R; Bhardwaj N; Yu M; Zhao Q; Kim-Schulze S; Sebra R; Zhu J; Gnjatic S; Sfakianos J; Pal SK
    Nat Med; 2023 Nov; 29(11):2825-2834. PubMed ID: 37783966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disitamab Vedotin Alone or in Combination With Immune Checkpoint Inhibitors in Bladder-Sparing Treatment of Muscle-Invasive Bladder Cancer: A Real-World Study.
    Wang A; Chen M; Li D; Shi J; Tang W; Zhang Z; Ren S
    Clin Genitourin Cancer; 2024 Jun; 22(3):102085. PubMed ID: 38636170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spatial Relationships in the Tumor Microenvironment Demonstrate Association with Pathologic Response to Neoadjuvant Chemoimmunotherapy in Muscle-invasive Bladder Cancer.
    Beckabir W; Wobker SE; Damrauer JS; Midkiff B; De la Cruz G; Makarov V; Flick L; Woodcock MG; Grivas P; Bjurlin MA; Harrison MR; Vincent BG; Rose TL; Gupta S; Kim WY; Milowsky MI
    Eur Urol; 2024 Mar; 85(3):242-253. PubMed ID: 38092611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: A cohort study.
    Chauhan PS; Chen K; Babbra RK; Feng W; Pejovic N; Nallicheri A; Harris PK; Dienstbach K; Atkocius A; Maguire L; Qaium F; Szymanski JJ; Baumann BC; Ding L; Cao D; Reimers MA; Kim EH; Smith ZL; Arora VK; Chaudhuri AA
    PLoS Med; 2021 Aug; 18(8):e1003732. PubMed ID: 34464379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 Trial of Atezolizumab Plus Trimodal Therapy in Patients With Localized Muscle-Invasive Bladder Cancer.
    Marcq G; Souhami L; Cury FL; Salimi A; Aprikian A; Tanguay S; Vanhuyse M; Rajan R; Brimo F; Mansure JJ; Kassouf W
    Int J Radiat Oncol Biol Phys; 2021 Jul; 110(3):738-741. PubMed ID: 33421558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does Bladder Cancer Subtype Influence Pathologic Complete Response (pCR) and Pelvic Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) Response Evaluation After Neoadjuvant Chemotherapy? Pathological Perspective.
    Kim JM; Choi E; Sung SH; Jo J; Lee DH; Park S
    Clin Genitourin Cancer; 2024 Apr; 22(2):224-236. PubMed ID: 38042728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.